EMA Says Yes To First Sickle Cell Drug For PRIME
Investigational drugs for sickle cell disease and diffuse large B cell lymphoma from Global Blood Therapeutics and Roche respectively have become the latest products to make it onto the European Medicines Agency’s PRIME scheme for speeding the development of drugs for unmet medical need.
You may also be interested in...
Roche will learn this week if two potential anticancers it is developing - polatuzumab vedotin and entrectinib - will be okayed for fast track regulatory review when they are filed in the EU.
With an eye on a patient population mainly covered by Medicare and Medicaid, Emmaus Life Sciences CEO Yutaka Niihara says the company wants to ensure its pharmaceutical grade L-glutamine product is accessible in the US.
Regulators in Pakistan are consulting on draft rules that outline their plan to introduce a risk management approach to their inspection activities and the frequency at which manufacturers can expect to undergo an inspection.